Real-World Study of the Safety and Efficacy of Surufatinib in the Treatment of Neuroendocrine Tumors

Inclusion criteria

• Patients with pathologically or cytologically confirmed neuroendocrine tumors;
• At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1;
• Life expectancy ≥ 12 weeks;
• Adequate organ and bone marrow function

Exclusion criteria

• Participation in other drug clinical trials with investigational drug treatment within the past 4 weeks;
• History of other malignancies within the past 5 years, except for curatively resected basal cell or squamous cell carcinoma of the skin, or cervical carcinoma in situ;
• Patients with contraindications to surufatinib (e.g., active bleeding, ulcer, intestinal perforation, intestinal obstruction, medically uncontrolled hypertension, grade III-IV cardiac dysfunction, within 30 days after major surgery, severe hepatic or renal impairment, etc.);
• Presence of any disease or condition that affects drug absorption, or inability to take surufatinib orally;
• Any condition deemed by the investigator as unsuitable for study drug treatment.